Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness

International Urology and Nephrology

Volumn 46, Issue 5, 2014, Pages 941-946

  Jiang, Wei ^a   Zheng, Yi ^a   Huang, Zhongxian ^a   Wang, Muwen ^a   Zhang, Yinan ^a   Wang, Zheng ^a   Jin, Xunbo ^a   Xia, Qinghua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Prostate cancer; SMAD4; TGF beta; Valproic acid

Indexed keywords

PROTEIN KINASE B; SMAD4 PROTEIN; VALPROIC ACID; ENZYME INHIBITOR; SMAD4 PROTEIN, HUMAN;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FILTERS AND MEMBRANES; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; TUMOR INVASION; WESTERN BLOTTING; CELL MOTION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROTEIN SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; SMAD4 PROTEIN; VALPROIC ACID;

EID: 84903594231     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0609-6     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer Statistics. Ca Cancer J Clin 63:11-30
2. Andreoiu M, Cheng L (2010) Multifocal prostate cancer: biologic, prognostic and therapeutic implications. Hum Pathol 41:781-793
3. Thiery JP, Acloque H, Huang RY et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890
4. Xu J, Lamouille S, Derynck R (2009) TGF-β-induced epithelial to mesenchymal transition. Cell Res 19:156-172
5. Takaku K, Oshima M, Miyoshi H et al (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92:645-656 (Pubitemid 28141513)
6. Aitchison AA, Veerakumarasivam A, Vias M et al (2008) Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 68:661-674 (Pubitemid 351614644)
7. Ding Z, Wu CJ, Chu GC et al (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 10:269-273
8. Kuo MH, Allis CD (1998) Roles of histone acetyltransferases and deacetylases in gene regulation. BioEssays 20:615-626
9. Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420-5432 (Pubitemid 47255924)
10. Mottet D, Castronovo V (2008) Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25:183-189
11. Zhongxian H, Xunbo J et al (2011) Effect of valproic acid on autophagy in prostate cancer PC3 cells. J SD 49(7):44-47
12. Xia Q, Sung J, Chowdhury W et al (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237-7244 (Pubitemid 44197704)
13. Gao D, Xia Q, Lv J et al (2007) Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Int J Urol 14:838-845 (Pubitemid 47313269)
14. Chen J, Ghazawi FM, Bakkar W et al (2006) Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 5:71-81
15. Feng XH, Derynck R (2005) Specificity and versatility in TGF-b signaling through Smads. Ann Rev Cell Dev Biol 21:659-693
16. MacGrogan D, Pegram M, Slamon D et al (1997) Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15:1111-1114 (Pubitemid 27401966)
17. Schutte M, Hruban RH, Hedrick L et al (1996) DPC4 gene in various tumor types. Cancer Res 56:2527-2530 (Pubitemid 26170688)
18. Gorlov IP, Sircar K, Zhao H et al (2010) Prioritizing genes associated with prostate cancer development. BMC Cancer 10:599-606
19. Ding Z, Wu CJ, Chu GC et al (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 10:269-273
20. Printz C (2011) Molecular predicator of metastatic cancer identified. Cancer 117:2827-2829
21. Kim CJ, Sakamoto K, Tambe Y et al (2011) Opposite regulation of epithelial-to- mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells. Int J Oncol 38:1759-1766
22. Lu K, Georg S, Huajie B et al (2012) Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3 K/AKT/PTEN pathway. Carcinogenesis 33:751-759
23. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604-610 (Pubitemid 351214528)
24. Halkidou K, Gaughan L, Cook S et al (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177-189 (Pubitemid 38481229)
25. Kim NH, Kim SN, Kim YK (2011) Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Biochem Biophys Res Commun 404:915-921
26. Rathkopf D, Wong BY, Ross RW et al (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66:181-189
27. Zhang L, Wang G, Wang L et al (2011) Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression. Pharmazie 66:614-618
28. Rathkopf D, Wong BY, Ross RW et al (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66:181-189
29. Ellis L, Lehet K, Ramakrishnan S et al (2011) Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PLoS One 6:e27178
30. Wedel S, Hudak L, Seibel JM et al (2011) Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer 11:375-389